跳至主要内容
临床试验/CTRI/2020/12/029590
CTRI/2020/12/029590已完成4 期

A prospective, randomized, double blind, placebo controlled, parallel arm study to assess the efficacy & safety of Oligocare Forte Plus versus placebo in sub-fertile males. - Nil

Meyer Organics Pvt Ltd0 个研究点目标入组 300 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Willingness to provide written informed consent to participate in the study and willing to follow up.
  • The female partner was defined as being fertile
  • Semen analysis indicating any 2 of the following criteria-
  • Semen volume <1.5ml
  • Sperm count < 15 x 106/ml
  • Motile count < 25% /106ml should read as Motile count <25%
  • Abnormal morphology < 4% normal form.
  • DNA fragmentation >20%
  • Subjects with Oligospermia, Asthenospermia, Teratospermia
  • Female partners of the male subjects with reported pre-existing fertility disorders can still be considered.

排除标准

  • General and endocrinological disease (clinical examination and routine
  • hormonal laboratory tests)
  • Previous or present cryptorchidism or genital obstruction.
  • H/o Vasectomy, undescended testis, prostate cancer, varicocele, hydrocele.
  • H/o chemotherapy or radiation for malignant conditions.
  • H/o Azoospermia

研究者

发起方
Meyer Organics Pvt Ltd

相似试验